Gan & Lee Pharmaceutical Company
Founded in 1998, Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China. Since its inauguration, Gan & Lee has been focusing on insulin production. In 1998, Gan & Lee successfully developed the first domestic biosynthetic human insulin, which was evaluated as China’s top 10 scientific and technological breakthroughs by Chinese Academy of Sciences and Engineering. Hitherto Gan & Lee has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin®, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25®, all of which have received high reputation from nationwide clinicians and patients, with outstanding efficacy and safety guarantees.
Industry:
PharmTech
Headquarters:
Beijing, Beijing, China
Zip:
1001-5000
Founded Date:
1998-01-01
Employees Number:
1001-5000
Acquisitions Number:
4
Investors Number:
46462082
Total Funding:
$100M to $500M
Estimated Revenue:
2020-06-28
Last Funding Date:
Private Equity
Last Funding Type:
info@ganlee.com
Register and Claim Ownership